Printer Friendly

ALPHA 1 BIOMEDICALS ANNOUNCES MANUFACTURING AGREEMENT FOR THYMOSIN ALPHA 1

 BETHESDA, Md., Sept. 13 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ Small Cap: ALBM), today announced that it has entered into a manufacturing agreement with UCB Bioproducts, S.A., subsidiary of UCB, a major pharmaceutical manufacturer located in Brussels, Belgium, for the production of bulk Thymosin alpha 1. It is anticipated that the product manufactured under the agreement initially will be used by Alpha 1 to supply Alpha 1's licensees.
 According to Vincent F. Simmon, Ph.D., the president and chief executive officer of Alpha 1, "This agreement was entered into in anticipation of orders from its licensees for commercial sales in Italy and Asia." In this regard, Dr. Simmon noted that Alpha 1's licensee, Sclavo, S.p.A., has received regulatory approval for the sale of Thymosin alpha 1 in Italy as an adjuvant for influenza vaccine in patients undergoing renal dialysis, and that Alpha 1's licensee, SciClone Pharmaceuticals, Inc., last week announced that it has received regulatory approval for the sale of Thymosin alpha 1 in Singapore for the treatment of chronic hepatitis B.
 "UCB Bioproducts has extensive peptide manufacturing experience and currently produces peptides that are being sold commercially by pharmaceutical companies as well as peptide products that are being used in clinical trials in the United States and other countries. Alpha 1 now has the necessary capacity to meet existing orders from both Sclavo and SciClone," said Dr. Simmon. Under the agreement, Alpha 1 will be providing UCB Bioproducts with certain technology, know-how, materials and procedures and will be actively participating with UCB Bioproducts in the manufacturing process. Delivery of Thymosin alpha 1 from UCB Bioproducts is scheduled to begin in the fourth quarter of 1993.
 Alpha 1 Biomedicals, Inc., is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 9/13/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc.; UCB Bioproducts, S.A. ST: Maryland IN: MTC SU:

TW-OS -- NY036 -- 1241 09/13/93 11:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:379
Previous Article:RECOGNITION REACHES OUT-OF-COURT SETTLEMENT
Next Article:WPXI-TV DROPPED FROM ARMSTRONG CABLE LINE-UP
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters